"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Long-term safety data with median follow-up of two years, and out to more than four years, demonstrate that tividenofusp alfa was generally well tolerated "Longer-term clinical data add to confidence ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

In patient-derived and animal tumour models, mubritinib suppressed glioblastoma stem cells and tumour growth by targeting ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Here, we experimentally examined diet-microbe- host interactions through a complex systems framework, centered on dietary oxalate. Using multiple, independent molecular, animal, and in vitro ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate ...

Purpose: To assess the effect of chronic exercise training on blood lactate metabolism at rest (i.e., basal lactate concentrations) and during exercise (i.e., blood lactate concentration at a fixed ...

This Research Topic is Volume II of the article collection. The previous volume, which has attracted over 23K views and 4K downloads, can be found here: Inborn errors of carbohydrate metabolism.